Avalo Therapeutics (AVTX) Liabilities from Discontinued Operations (2018 - 2021)

Avalo Therapeutics has reported Liabilities from Discontinued Operations for 4 years, with the latest figure at 10000.0 in Q3 2021.

• For the quarter ending Q3 2021, Liabilities from Discontinued Operations changed N/A year-over-year to 10000.0; the trailing twelve-month figure through Sep 2021 stood at 10000.0 (changed N/A YoY), and the FY2020 full-year result was 1341000.0, down 65.54% from the prior year.
• Liabilities from Discontinued Operations for Q3 2021 stood at 10000.0, down from 98000.0 in the prior quarter.
• The five-year high for Liabilities from Discontinued Operations was 7549631.0 in Q4 2018, with the low at 10000.0 in Q3 2021.
• Historically, Liabilities from Discontinued Operations has averaged 2183107.17 across 4 years, with a median of 775000.0 in 2020.
• Annual changes were most pronounced in 2019 — Liabilities from Discontinued Operations plunged 48.46% — and 2020, when it plunged 65.54%.
• Avalo Therapeutics' Liabilities from Discontinued Operations stood at 7549631.0 in 2018, then plunged by 48.46% to 3891012.0 in 2019, then sank by 65.54% to 1341000.0 in 2020, then plunged by 99.25% to 10000.0 in 2021.
• The last three Liabilities from Discontinued Operations figures came in at 10000.0 (Q3 2021), 98000.0 (Q2 2021), and 209000.0 (Q1 2021), per Business Quant data.